Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154401 | 0.73 | — | — | |
| SCHEMBL6412576 | 0.73 | — | — | |
| SCHEMBL24145265 | 0.73 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL14892385 | 0.69 | — | — | |
| SCHEMBL13037485 | 0.69 | — | — | |
| SCHEMBL4569589 | 0.69 | — | — | |
| SCHEMBL279210 | 0.67 | — | — | |
| SCHEMBL19242814 | 0.67 | — | — | |
| SCHEMBL19829087 | 0.67 | — | — | |
| SCHEMBL12991243 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160016957-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9181221-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | ALDH1A1 4410/4885MAPT 1518/4885 |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | ALDH1A1 4410/4885MAPT 1518/4885 |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | ALDH1A1 1435/4885MAPT 3416/4885 |
| US-20160016957-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | ALDH1A1 4410/4885MAPT 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.